Hepatitis B virus genotyping among chronic hepatitis B patients with resistance to treatment with lamivudine in the City of Ribeirão Preto, State of São Paulo

Genotipagem do vírus da hepatite B de pacientes crônicos com resistência ao tratamento com lamivudina na Cidade de Ribeirão Preto, Estado de São Paulo

Rodrigo Haddad¹, Ana de Lourdes Candolo Martinelli², Sérgio Akira Uyemura³ and Jonny Yokosawa³

ABSTRACT

Introduction: Lamivudine is a nucleoside analogue that is used clinically for treating chronic hepatitis B infection. However, the main problem with prolonged use of lamivudine is the development of viral resistance to the treatment. Mutations in the YMDD motif of the hepatitis B virus DNA polymerase gene have been associated with resistance to drug therapy. So far, there have not been many studies in Brazil reporting on genotype-dependent development of resistance to lamivudine. Thus, the aim of the present study was to determine the possible correlation between a certain genotype and increased development of resistance to lamivudine among chronic hepatitis B patients.

Methods: HBV DNA in samples from 50 patients under lamivudine treatment was amplified by means of conventional PCR. Samples were collected at Hospital das Clínicas, FMRP-USP. The products were then sequenced and phylogenetic analysis was performed.

Results: Phylogenetic analysis revealed that 29 (58%) patients were infected with genotype D, 20 (40%) with genotype A and one (2%) with genotype F. Mutations in the YMDD motif occurred in 20% of the patients with genotype A and 27.6% of the patients with genotype D.

Conclusions: Despite the small number of samples, our results indicated that mutations in the YMDD motif were 1.38 times more frequent in genotype D than in genotype A.

Key-words: Hepatitis B. Lamivudine. YMDD. HBV genotype.

INTRODUCTION

Hepatitis B is a public health problem of worldwide importance. Approximately 350 million people are chronic carriers and one third of the world’s population has been in contact with the hepatitis B virus (HBV)¹. Chronic carriers are exposed to the development of complications arising from hepatitis B infection, resulting in cirrhosis, hepatocellular carcinoma, liver failure or death²⁻⁴. HBV is an enveloped virus that belongs to the Hepadnaviridae family. The viral genome consists of partially double-stranded circular DNA of approximately 3,200 base pairs. It codes for the small (S), medium (M) and large (L) surface antigens (HBsAg), the core protein (HBcAg), a soluble core protein (HBeAg), a protein of unknown function (X) and the viral polymerase. Although HBV is a DNA virus, a genomic RNA strand is reverse transcribed into DNA by the viral polymerase during the viral replication cycle. This enzyme does not have proofreading repair activity, and this leads to potential errors during reverse transcription.

Chronic infection may be associated with high or low levels of viral replication, and with severe or absent inflammatory response in the liver. When the inflammatory response is absent or mild, antiviral therapy is not indicated¹. Treatment is indicated in HBsAg-positive patients with compensated liver disease who are either HBeAg positive or HBeAg negative and who have serum alanine aminotransferase (ALT) levels greater than or equal to twice the upper limit of normal and HBV DNA levels (≥ 10⁵ copies/ml)⁵. The aims of treatment in chronic hepatitis B cases are to achieve sustained suppression of HBV replication and remission of the liver disease. The endpoints used to assess treatment response include normalization of serum ALT level, undetectable serum HBV DNA in a non-amplifying assay, loss of HBeAg with or without detection of anti-HBe antibodies, and improvement in liver histology⁶. 
Interferon-α (INF-α) was the only available therapeutic option for chronic hepatitis B until a few years ago. However, the efficacy of IFN-α was rather limited. The development of nucleoside analogues has been a major advance in hepatitis B treatment. Some nucleoside analogues have excellent oral availability, a good safety record and antiviral efficacy comparable to that observed with interferon-α 2β.

Lamivudine, also known in the literature as (-)SddC, (-)BCH-189 and (-)3TC, is the minus enantiomer of β-L-2',3'-dideoxy-3'-thiacytidine. It is an oral cytosine analogue that is clinically used for treating chronic HBV infection. It potently inhibits HBV replication by interfering with the reverse transcriptase activity of the viral polymerase, which results in a marked decrease of HBV DNA and ALT levels, seroconversion of HBeAg to anti-HBe, and histopathological improvement. However, one major problem with long-term use of lamivudine is the potential development of viral resistance, associated with increases in HBV DNA and serum transaminases. The incidence of drug-resistant hepatitis B virus during lamivudine treatment is 14-36% after one year of treatment and increases to 38%, 49% and 66% after two, three and four years of treatment, respectively.

In most patients with lamivudine resistance, substitutions of the amino acid methionine at position 204 in the YMDD motif of the viral polymerase by either valine (M204V, YVDD) or isoleucine (M204I, YIDD) have been reported. The mutation M204V is the most common and is accompanied by the leucine-to-methionine substitution at amino acid position 180 (L180M).

Eight hepatitis B virus genotypes have been recognized (A-G). Brazil is a country geographically divided into several regions that have been colonized by people of different ethnic backgrounds. Therefore, HBV genotype distribution may differ in these regions. The genotypes A, D and F are the most prevalent, but genotypes C and G have also been reported. In addition, there have been few studies describing the genotype-dependent development of resistance to lamivudine in HBV.

The main objective of the present study was to determine the possible genotype-dependency related to the development of resistance to lamivudine among chronic hepatitis B patients treated at Hospital das Clínicas of Ribeirão Preto, University of São Paulo, in southeastern Brazil.

### METHODS

#### Clinical samples

Serum samples were collected from 50 patients (Table 1) who had chronic hepatitis B and received lamivudine therapy. The samples were obtained at the Gastroenterology Department of Hospital das Clínicas de Ribeirão Preto, Ribeirão Preto School of Medicine, University of São Paulo. These samples were grouped according to the following parameters: (1) regarding patients who responded to therapy, samples were collected before the treatment, and regarding patients whose response to therapy could not be determined because of lack of follow-up, the last sample that was collected was used; (2) regarding patients who did not respond to therapy, serum samples were collected either during or after the treatment.

#### HBV DNA extraction, PCR amplification and purification

HBV DNA was extracted from 200µl of serum samples using the MasterPure™ Complete DNA and RNA Purification Kit (EPICENTRE® Biotechnologies. Madison, WI, USA), in accordance with the manufacturer’s instructions. Part of the polymerase gene (positions 55 to 1,197) was amplified by means of PCR in a 50µl reaction containing 5µl of extracted DNA, 10mM Tris-HCl, 1.5mM MgCl₂, 50mM KCl, 0.2mM of each dNTPs, 0.3µM of primers P1F and P1R, and 1.25 units of Taq Polymerase (Roche Diagnostics GmbH, Mannheim, Germany). Forty cycles of amplification were performed under these conditions: denaturation at 94°C for 30 seconds, annealing at 50°C for 30 seconds and elongation at 72°C for 2 minutes. For some samples that did not produce successful amplification, nested PCR was performed using 2µl of the first PCR product, i.e. primers P4F and P2R (positions 230 to 1,017) under the same thermal profile, except for annealing (55°C for 30 seconds). The PCR products were analyzed by means of electrophoresis on agarose gel (1% w/v).

#### Sequencing

PCR product purification was performed using the QIAquick PCR Purification Kit (QIAGEN GmbH, Hilden, Germany), in accordance with the manufacturer’s instructions. Part of the polymerase gene (including the YMDD motif) was sequenced by using the BigDye™ Cycle Sequencing kit, v. 3.1 (Applied Biosystems, Foster City, CA, USA) in a 20µl reaction containing 2µl of the BigDye reagent, 10 to 40ng of purified PCR DNA, 3.2 pmol of primer and deionized water. The thermal cycles were: 96°C for 10 seconds, for denaturation; 50°C for 30 seconds and elongation at 72°C for 2 minutes. For some samples that did not produce successful amplification, nested PCR was performed using 2µl of the first PCR product, i.e. primers P4F and P2R (positions 230 to 1,017) under the same thermal profile, except for annealing (55°C for 30 seconds). The PCR products were analyzed by means of electrophoresis on agarose gel (1% w/v).

#### Determination of viral genotype by phylogenetic analysis

After sequencing of the samples, nucleotide sequences were analyzed and edited using Seqman™ (DNASTAR, Inc. Madison, WI, USA). The edited sequences (GenBank databases accession numbers, HBV0001: EU221426; HBV0002: EU221427; HBV0003: EU221428; HBV0004: EU221429; HBV0006: EU221430; HBV0007: EU221431; HBV0008: EU221432; HBV0009: EU221433; HBV0010: EU221434; HBV0011: EU221435; HBV0014: EU221436; HBV0016: EU221437; HBV0018: EU221438; HBV0019: EU221439; HBV0020: EU221440; HBV0024: EU221441; HBV0025: EU221442; HBV0026: EU221443; HBV0029: EU221444; HBV0030: EU221445; HBV0031: EU221446; HBV0032: EU221447; HBV0033: EU221448; HBV0034: EU221449; HBV0036: EU221450; HBV0037: EU221451; HBV0038: EU221452; HBV0039: EU221453; HBV0040: EU221454; HBV0041: EU221455; HBV0042: EU221456; HBV0045: EU221457; HBV0047: EU221458; HBV0048: EU221459; HBV0050: EU221460; HBV0051: EU221461; HBV0052: EU221462; HBV0053: EU221463; HBV0055: EU221464; HBV0056: EU221465; HBV0057: EU221466; HBV0058: EU221467; HBV0059: EU221468; HBV0061: EU221469; HBV0062: EU221470; HBV0064: EU221471; HBV0065: EU221472; HBV0066: EU221473; HBV0068: EU221474; HBV0069: EU221475) were aligned with 20 reference sequences.
that included all genotypes, which were obtained from GenBank (accession numbers for Genotype A: Z35717; X51970; M57663. Genotype B: D50521; X78751; M54923. Genotype C: D23682; D50517; X75665. Genotype D: M32138; X97849; X65257. Genotype E: X75664; X75667. Genotype F: AB036910; X75663; X69798. Genotype G: AB056515; AB064313; AF160501) using MegAlign\textsuperscript{TM} (DNASTAR). The sequence of the woolly monkey HBV (WMHBV, accession number AF046996) was used as an out-group to root the phylogenetic tree. The distance matrix was constructed using the DNADIST program, and the phylogenetic analysis was done using a neighbor-joining method. The Kimura-2-parameter substitution model was run using the neighbor-joining program. Bootstrapping was performed with 1,000 replicates using the Seqboot program to assess the robustness of the tree. Finally, phylogenetic trees were built using the Treeview 1.4 program. DNADIST, Neighbor-joining, Seqboot and Treeview 1.4 are programs within the PHYLIP package, version 3.5c\textsuperscript{26}. Statistical analysis (Fisher’s exact test) was performed to observe the relationship between mutations and genotypes.

**Ethical**

This study was approved by the Ethics Committee of Hospital das Clínicas de Ribeirão Preto and informed consent was obtained from all patients.

**RESULTS**

**Genotyping**

The PCR products from the samples were sequenced and phylogenetic analysis (Figure 1) was performed on the 50 sequences using the neighbor-joining method. It was found that 29 (58%) patients were infected with HBV genotype D, 20 (40%) with HBV genotype A and one (2%) with HBV genotype F.

**YMDD motif variants**

Deduced amino acid sequences were obtained in order to detect the lamivudine resistance substitutions in the YMDD motif. Among the four lamivudine-resistant samples of genotype A, all of them presented YVDD variants, and among the samples of the genotype D, four (50%) presented YVDD variants and four (50%) presented YIDD variants. All samples that presented YVDD variants, regardless of the genotype, also presented another substitution at amino acid position 180 (L180M).

**YMDD variants and HBV genotype**

Although the statistical analysis did not show significant results, our sequence analyses showed that substitutions in the YMDD motif appeared in 20% (4/20) of the samples of genotype A and in approximately 27.6% (8/29) of the samples of genotype D. These observations denote that the likelihood that YMDD substitution presenting resistance to lamivudine might appear was approximately 37.9% higher in patients with genotype D than in those with genotype A.

**DISCUSSION**

Hepadnaviruses are the only DNA viruses that, similar to retroviruses, utilize a reverse transcription step in the replication of the viral genome. Reverse transcription is an error-prone process\textsuperscript{27} and, similar to what happens with human immunodeficiency virus (HIV) and human T-cell leukemia virus (HTLV), this process results in the appearance of HBV subpopulations known as quasispecies. These contain nucleotide substitutions within the viral genome in infected individuals\textsuperscript{28}. The frequency of HBV mutations has been estimated to be approximately 1.4 to 3.2 x 10\textsuperscript{-5} nt substitutions per site per year, which is about ten times higher than the rates for other DNA viruses. The magnitude and rate of virus replication are also important in the process of mutation generation\textsuperscript{29}. Mutations may lead some variants to escape the immunological defense system\textsuperscript{30}, antiviral treatment\textsuperscript{31} or vaccine protection\textsuperscript{32}. In the case of HBV, reverse transcription is carried out through viral polymerase. Substitutions in domain C, especially in the YMDD motif, lead to resistance to lamivudine treatment\textsuperscript{33}.

In the present study, twelve samples presented these substitutions. Eight of these samples presented a YVDD variant (M204V) and four
presented a YIDD variant (M204I). These results are concordant with other studies that described YVDD as the most frequent variant, followed by the YIDD variant. Moreover, our samples with M204V substitution were always in combination with the mutation L180M, while the samples with M204I substitution were not. These data are concordant with other studies that reported that the substitution M204V develops in combination with the substitution L180M, whereas the substitution M204I usually emerges alone. Data from in vitro studies have shown that M204V substitution alone confers less resistance than the M204I substitution, which might explain the fact that M204V and L180M substitutions usually occur in association. Thus, this association may occur in vivo to improve replication fitness in the presence of lamivudine. Studies on the biological behavior of the resistant mutant strains in cell cultures have shown that the replication rate of both variants, M204V and M204I, is much lower than that of the wild HBV. Moreover, further studies suggest that restoration of the replication rate occurs with the addition of the L180M mutation, which we also observed.

These resistant variants may appear after six months of lamivudine therapy, but the likelihood that resistance may appear possibly increases with longer periods of treatment. In the present study, only 16.7% (2/12) of the cases presented substitutions related to lamivudine resistance during the first year of treatment (data not shown).

Genotype distribution studies on HBV in Brazil are rare, and the number of strains analyzed is still insufficient for better understanding of genotype distribution in this country. Data from other studies indicate that genotypes A, D and F are present in Brazil. In our study, we observed the presence of these genotypes. Although our data differ in genotype distribution, in relation to data from other regions in Brazil, these results are concordant with another study reported by Resende et al. from the same region, where genotype D is the most prevalent followed by genotypes A and F.

Few studies have been carried out in order to establish relatedness between resistance to lamivudine treatment and HBV genotype. In a study on patients infected with HBV of genotypes B and C, Kao did not observe any differences in the likelihood of development of resistance to lamivudine. On the other hand, Pan et al. showed that although there are no differences between these HBV genotypes and resistance to lamivudine, the likelihood that the YVDD variant might emerge was higher with genotype B than with genotype C. In a study on patients infected with HBV of genotypes A, B and C, Akuta et al. suggested that resistance to lamivudine was not genotype-dependent. However, in the same study, patients infected with one subgroup of genotype B (Ba), named the Asiatic subgroup, presented emergence of a significantly higher rate of resistance than observed in another genotype B (Bj) subgroup, named the Japan subgroup. Zöllner et al. showed the existence of differences in mutational profile during the lamivudine resistance selection between genotypes A and D, but did not show the possibility that these genotypes might develop resistant variants at different rates. Other recent studies have suggested that the rate of lamivudine resistance was higher among patients infected with HBV genotype A than among those with genotype D.

In Brazil, some studies have observed this relationship but, like in the present study, the number of samples was insufficient to correlate lamivudine resistance mutations and genotype. Studies with large number of samples need to be performed in order to clarify the role of HBV genotype and treatment response. Although 20 HBV samples were collected from patients that showed resistance to treatment with lamivudine, only 12 samples showed substitution in the YMDD motif. Some of the patients did not follow the physician’s recommendations and did not take lamivudine accordingly. Furthermore, we detected, in one of the patients, a mutation in the YMDD motif before the beginning of the lamivudine treatment. This patient did not return and therefore no follow-up specimens were obtained. Despite the low number of samples, our results show a difference in the rate of appearance of resistance-related substitutions. The appearance of mutations in HBV cases was 1.38 times more frequent in genotype D than in genotype A. There is an essential need to continue investigating this relatedness with a larger number of samples, in order to confirm our results.

**CONFLICT OF INTEREST**

The authors declare that there is no conflict of interest.

**FINANCIAL SUPPORT**

FCFRP-USP, CAPES.

**REFERENCES**

6. Wright TL. Clinical Trial Results and Treatment Resistance with lamivudine in hepatitis B. Semin Liver Dis 2004; 24:31-36.
7. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatol 2001; 34:1225-1241.
Clinical relevance of hepatitis B genotypes: A case of déjà vu? J C E.

34. Lok AS, Hussain M, Cursano C, W MPFMB.

33. Chen WN, Oon CJ. Hepatitis B virus mutants: An overview. J Gastroenterol


28. Torresi J.

27. Domingo E, Holland JJ. RNA virus mutations and fitness for survival. Annu Rev


24.

23.

22. Moraes MTB, Gomes SA, Niel C. Sequence analysis of pre S/S gene of hepatitis B

21. Niel C, Moraes MTB, Gaspar AMC, Yoshida CFT, Gomes AS. Genetic diversity

20.

19.

18.


geneotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen


2. Felsenstein J. PHYLIP (Phylogeny Inference Package). Distributed by the author.

1. Domingo E, Holland JJ. RNA virus mutations and fitness for survival. Annu Rev


to long-term lamivudine treatment in patients infected with hepatitis B virus